Media coverage about Entellus Medical (NASDAQ:ENTL) has been trending positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Entellus Medical earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news headlines about the medical technology company an impact score of 45.7457387117323 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of NASDAQ ENTL traded down $0.01 on Wednesday, reaching $24.00. 43,800 shares of the company traded hands, compared to its average volume of 178,331. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.
Several research analysts recently weighed in on ENTL shares. Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 17th. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. Finally, ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.33.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.